评估Helicobacter pylori感染作为缺铁性贫血的危险因素:一个病例控制方法
Dipendra Singh1, Varun Upadhyay2, Sunny Bhushan Singh2
1Orthopedics, Soo-Jung Hospital Doti, Rajpur Doti, NPL.
Cureus
|June 18, 2025
概括
杆菌感染与缺铁性贫血 (IDA) 密切相关. 根除H. pylori可能有助于管理和解决IDA,特别是在营养不良或使用NSAID的患者中.
科学领域:
- 医学科学 医学科学 医学科学
- 胃肠病学 胃肠病学
- 血液学 血液学 血液学
背景情况:
- 杆菌感染越来越多地被认为是导致胃肠外问题的原因,特别是缺铁性贫血 (IDA).
- 了解H. pylori和IDA之间的关系对于有效的患者管理至关重要.
研究的目的:
- 通过一项病例对照研究,调查Helicobacter pylori感染和缺铁性贫血之间的关联.
- 分析与健康对照组相比,IDA患者中H. pylori的患病率.
主要方法:
- 一项涉及48名参与者的病例控制研究 (24名IDA病例,24名对照) 根据年龄和性别进行了匹配.
- 通过便抗原或尿素呼吸试验评估H. pylori感染;收集有关饮食,NSAID使用和症状的数据.
- 使用独立的t测试和千平方测试进行统计分析 (p < 0.05显著性).
主要成果:
- 在IDA患者 (87.5%) 与对照组 (29.2%) (p < 0.001) 中,H. pylori阳性显著更高.
- IDA病例显示血红蛋白,费里丁和血清铁水平较低,总铁结合能力较高.
- 营养状况不佳和NSAID使用在H. pylori阳性个体中更常见.
结论:
- 铁杆菌感染直接与缺铁性贫血的发展有关.
- 对H. pylori感染的综合评估和治疗显示出对管理IDA的希望,特别是在风险人群中.
更多相关视频
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
282
03:33Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
Published on: May 23, 2025
236
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
561
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
561
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
212
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
212
01:30Peptic Ulcer Disease I: Introduction
305
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
305
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
732
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
732
01:23Gastritis III: Clinical Manifestations and Management
506
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
506
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
609
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
609